Skip to content
Screener

Syndax Pharmaceuticals SNDX Business Segments — Stock Based Compensation

Similar metrics at other companies

PPL logo
PPLStock Based Compensation
$9M+50.0%
Popular logo
BPOPStock Based Compensation
$6.58M-39.7%
Claritev Corporation logo
CTEVReportable Segment — Stock Based Compensation
$6.42M-2.4%
Fulgent Genetics, Inc. logo
FLGTTherapeutic Development — Allocated Share Based Compensation Expense
$2.25M+11.5%
Ligand Pharmaceuticals logo
LGNDDevelopment and Licensing of Biopharmaceutical Assets — Stock-Based Comp
$13.65M+36.6%
Veracyte logo
VCYTBiopharmaceutical and other revenue — Compensation expense
$0-100%

Other financials

Income statement

See full
Revenue$64.9M+224%
Operating income-$34.2M+59.2%
Net income-$42.7M+49.7%
EPS (diluted)-$0.48+51.0%

Balance sheet

See full
Cash & equivalents$130.9M-15.0%
Total debt$350.5M+4.2%
Total equity$41.6M-80.6%
Total assets$472.7M-26.2%

Cash flow

See full
Operating cash flow-$50.3M+47.1%
CapEx$46.8K—
Free cash flow-$80.8M-17.6%

Valuation

See full
Market cap$1.82B+69.0%
Enterprise value$2.04B+57.0%
P/S8.4×-5.4×

Profitability

See full
Operating margin-102.8%-47.8pp
Net margin-111.9%-51.5pp
FCF margin-187.2%-85.4pp

Returns & leverage

See full
Return on equity-189.5%-8,509pp
Debt / equity8.4×+6.9×
Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept sndx:StockBasedCompensation.

The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:04 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-197154
March 31, 2026Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Commercial related expenses7,72110,825
Personnel cost and other expenses16,70119,082
Other SG&A expenses5,1404,412
Stock-based compensation12,05310,380
Royalty interest expense11,8468,049
Interest expense (income), net(3,561)(7,181)
Other expense, net186221
Segment net loss$(42,673)$(84,846)

Item 1: Financial Statements

FAQ

What is Syndax Pharmaceuticals's business segments — stock based compensation?
Syndax Pharmaceuticals (SNDX) reported business segments — stock based compensation of $12.05M in Q1 2026.
How has Syndax Pharmaceuticals's business segments — stock based compensation changed year-over-year?
Syndax Pharmaceuticals's business segments — stock based compensation increased by 16.1% year-over-year, from $10.38M to $12.05M.
What does business segments — stock based compensation mean?
This metric reflects the non-cash expense recognized for equity-based awards granted to employees and executives within the cancer therapeutics segment. It is a key component of total compensation strategy used to attract and retain talent in the competitive biopharmaceutical industry. Investors analyze this to understand the impact of dilution and non-cash charges on overall profitability.

Ask your AI about Syndax Pharmaceuticals's business segments — stock based compensation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude